Professor Subrata Ghosh MD, FRCP, FRCPE, FRCPC, FCAHS

Image of Subrata Ghosh

Institute of Immunology and Immunotherapy
Professor of Translational Medicine
Director of the Institute of Translational Medicine

Contact details

Institute of Translational Medicine
College of Medical and Dental Sciences
University of Birmingham
B15 2TT

My interest and vision are to enable and synergise scientific discoveries into rapid translation to bedside of patients for their benefit. I am especially interested in immune mediated inflammatory diseases such as Crohn’s disease and Ulcerative colitis.


  • F.R.C.P.C, Royal College of Physicians and Surgeons of Canada, 2009
  • F.R.C.P.(London), Royal College of Physicians of London, 2002
  • F.R.C.P.(Edinburgh), Royal College of Physicians of Edinburgh, 1997
  • Doctorate of Medicine (Research), in Gastroenterology, University of Edinburgh, 1996
  • ECFMG (steps 1 & 2), 1991
  • MRCP (London), Royal College of Physicians of London, 1988
  • Diplomate National Board, National Board of Examinations, India, 1987
  • MD (Internal Medicine), University of Calcutta, India (postgraduate degree in internal Medicine), 1986
  • Bachelor of Medicine & Surgery (MBBS), University of Calcutta, India, 1982


Subrata Ghosh is the Director of the Institute of Translational Medicine and Professor of Translational Medicine, University of Birmingham. He took up this position on the 1st of June 2016. He moved from Canada where he was the Professor of Medicine at University of Calgary. He was cross-appointed as Professor of Immunology and microbiology and was an adjunct Professor in the department of veterinary medicine. He was the Head of the Department of Medicine at Cumming School of Medicine, University of Calgary and the Zone Clinical Department Head, Calgary Zone, Alberta Health Services. Previously, he was the Chair of Gastroenterology and Professor of Gastroenterology at the Imperial College London, Hammersmith Hospital and associate professor of gastroenterology at University of Edinburgh.  Dr Ghosh is a Fellow of the Canadian Academy of Health Sciences and a member of the International Organization for the Study of IBD. He is a past editor in chief of the Canadian Journal of Gastroenterology and Hepatology and associate editor of Gut, and sits on the editorial boards of several journals. He served on the Scientific Advisory Committee of the Crohn’s and Colitis Canada and Chaired its of Advocacy Committee and he was the chairman of the medical advisors of the Crohn’s and Colitis UK. Dr Ghosh has published over 398 manuscripts (h index 61). He has delivered over 600 international lectures. His research interests are focused on translational immunology of inflammatory bowel disease and novel therapeutic approaches.

Postgraduate supervision

Subrata has supervised over 20 PhD students and his laboratory is open.

If you are interested in studying with Subrata, please contact him on the contact details above, or for any general doctoral research enquiries, please email: or call +44 (0)121 414 5005.

For a full list of available Doctoral Research opportunities, please visit our Doctoral Research programme listings.


My research interests span aetiopathology of IBD, immune disorders in IBD, Biomarkers in IBD, Treatment of IBD. A major focus is on dendritic cell and T cell interactions in IBD and targeting these interactions by pharmacological targeted therapies as well as by nutrient modulation.

Other activities

  • Nominated member International Organization for Study of IBD
  • Fellow of the Canadian Association of Health Sciences
  • Crohn’s and Colitis Canada –member of the scientific advisory board
  • Crohn’s and Colitis Canada – chairman of the advocacy committee
  • Crohn’s and Colitis UK- chairman of the medical advisors group


Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S and Niezychowski W; Study A3921063 Investigators (2012) Tofacitinib, an oral janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 367(7):616-24

Vermiere S, Ghosh S, Panes J, Dahlerup J, Luegering A, Sirotiakova J, Strauch U, Burgess G, Spanton J, Martin S and Niezychowski W (2011) The mucosal Addressin Cell Adhesion Molecule (MAdCAM) Antibody PF-00547,659 in ulcerative colitis: a randomized study. Gut 60(8):1068-75

Akbar A, Yiangou Y, Facer P, Walters JRF, Brydon WG, Anand P and Ghosh S (2010) Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain. Gut 59(6):767-74

Akbar A, Yiangou Y, Facer P, Walters JR, Anand P and Ghosh S (2008) Increased capsaicin receptor TRPV1 expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut 57(7):923-9

Marion-Letellier R, Butler M, Dechelotte P, Playford RJ and Ghosh S (2008) Comparison of cytokine modulation by natural PPARg ligands with synthetic ligands in intestinal-like Caco-2 cells – potential for dietary modulation of PPARg in intestinal inflammation. Am J Clin Nutr 87(4):939-48

Marchbank T, Mahmood A, Fitzgerald AJ, Domin J, Butler M, Goodlad RA, Elia G, Cox HM, Van Heel DA, Ghosh S and Playford RJ (2007) Human pancreatic secretory trypsin inhibitor stabilizes intestinal mucosa against noxious agents. Am J Pathol 171(5):1462-73

Van Heel DA, Ghosh S, Butler M, Hunt KA, Lundberg A, Ahmad T, McGovern DPB, Onnie C, Negoro K, Goldthorpe S, Foxwell BM, Mathew CG, Forbes A, Jewell DP and Playford RJ (2005) Muramyl dipeptide and toll-like receptor sensitivity in NOD2 associated Crohn’s disease. Lancet 365(9473):1794-6

Dennis MS, Lewis SC and Warlow C; The FOOD collaboration trial (2005) Routine oral nutritional supplementation for stroke patients in hospital (FOOD): a multicentre randomized controlled trial. Lancet 365(9461):755-63

Dennis MS, Lewis SC and Warlow C; The FOOD trial collaboration (2005) Effect of timing and method of enteral tube feeding for dysphagic stroke patients (FOOD): a multicentre randomized controlled trial. Lancet 365(9461):764-72

Armitage EL, Aldhous MC, Anderson N, Drummond HE, Riemersma RA, Ghosh S and Satsangi J (2004) Incidence of juvenile-onset Crohn’s disease in Scotland: Association with northern latitude and affluence. Gastroenterology 127(4):1051-7

Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnalek P, Zadarova Z, Palmer T and Donoghue S; Natalizumab Pan-European Study Group (2003) Natalizumab for active Crohn’s disease. N Engl J Med 348(1):24-32

Shmakov AN, McLennan NF, McBride P, Farquhar CF, Bode J, Rennison KA and Ghosh S (2000) Cellular prion protein is expressed in the human enteric nervous system. Nat Med 6(8):840-1

Afzal MA, Minor PD, Begley J, Bentley ML, Armitage E, Ghosh S and Ferguson A (1998) Absence of measles-virus genome in inflammatory bowel disease. Lancet 351(9103):646-7

Ghosh S, Cowen S, Hannan WJ and Ferguson A (1994) Low bone mineral density in Crohn’s disease but not in ulcerative colitis, at diagnosis. Gastroenterology 107(4):1031-9

View all publications in research portal